ClinicalTrials.gg
CompletedNCT03422250NetCogBsUpdated May 19, 2021Results posted

Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia

An interventional study of transcranial direct current stimulation (tDCS) in Alzheimer's Disease and Frontotemporal Dementia, Behavioral Variant, sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Completed at 1 site in Italy. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jun 2015, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 206 studies in Alzheimer Disease with a site in Italy — 54 open to participants now, 73 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Enrollment
152nd of 170
45 · median 328
Started
2015
with 7 others
No phase
54 of 206
21 open now
Registered
82nd of 206
by date
Lead sponsor
6 of 206
IRCCS Centro San Giovanni di Dio Fatebenefratelli

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 152nd largest by enrollment of the 170 interventional ones that give a count, is one of 8 that started in 2015, is one of 54 with no phase, and was the 82nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

This pilot study aims to test clinical and connectivity changes following non-invasive stimulation of disease-specific networks in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD). Brain network stimulation will be carried out with transcranial direct current stimulation (tDCS). Target networks will be the default mode network (DMN) and salience network (SN). Twenty AD and 20 bvFTD patients will be recruited and assessed with a comprehensive clinical, behavioral and cognitive battery, and 3 Tesla MRI scan (including resting-state functional MRI, arterial spin labeling, diffusion tensor imaging, structural MRI) at three time-points: baseline, after tDCS, and after 6 months. Patients will be randomized to 2 arms: anodal stimulation of the disease-specific network (DMN in AD, SN in bvFTD) or cathodal stimulation of the anti-correlated network (SN in AD, DMN in bvFTD). The intervention will consist of 10 tDCS sessions over two weeks. Cerebrospinal fluid (CSF) samples will be collected at baseline for biomarker's assessment; blood samples will be collected at each time-point to assess changes in peripheral inflammatory markers. Blood and CSF collection will be optional. A sample of 20 elderly controls will be included for baseline comparisons.

03

Conditions studied

  • Alzheimer's Disease
  • Frontotemporal Dementia, Behavioral Variant

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of AD or bvFTD according to current clinical criteria (Albert et al., 2011; Rascovsky et al., 2011)
  • Ability to provide written
  • Availability of a collateral source

Exclusion Criteria:

  • Moderate/severe dementia
  • Presence of any medical or psychiatric illness that could interfere in completing assessments

Exclusion Criteria for MRI and tDCS:

  • metal implants, pace-makers, prosthetic heart valves
  • claustrophobia
  • history of epilepsy
  • pregnancy

Exclusion Criteria for controls:

  • Current or past history of clinical, neurological, or psychiatric conditions that could interfere with the assessment (e.g., , ictus, head trauma, epilepsy, multiple sclerosis, neuropathy, mood disorders, substance abuse)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Arm 1

    Alzheimer's disease (AD): anodal tDCS of the default mode network (DMN)

    Device: transcranial direct current stimulation (tDCS)

  • Experimental
    Arm 2

    Alzheimer's disease (AD): cathodal tDCS of the salience network (SN)

    Device: transcranial direct current stimulation (tDCS)

  • Experimental
    Arm 3

    Behavioral-variant frontotemporal dementia (bvFTD): anodal tDCS of the salience network (SN)

    Device: transcranial direct current stimulation (tDCS)

  • Experimental
    Arm 4

    Behavioral-variant frontotemporal dementia (bvFTD): cathodal tDCS of the default mode network (DMN)

    Device: transcranial direct current stimulation (tDCS)

Interventions

  • Devicetranscranial direct current stimulation (tDCS)

    10 daily 25-minutes tDCS sessions over two weeks.

06

What researchers measure

Primary outcomes

  1. Change in Clinical Disease Severity (CDR)

    CDR - Clinical Dementia Rating score The clinical dementia rating (CDR) is a clinical global rating scale administered to both the participant and the caregiver, assessing 6 domains of participant function: memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care. Each domain is based on a 5-point scale ranging from no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 to severe impairment=3. The global CDR score is computed via a memory-weighted averaging algorithm of the six domain scores and ranges from 0 to 5. The CDR-sum of boxes (CDR-SB) is the sum of the individual domain scores and ranges from 0 to 18. Higher scores indicate more clinical impairment. Negative changes at post tDCS compared to baseline represent an improvement on the scale.

    Time frame: Baseline, post tDCS (week 3)

  2. Change in Behavioral Symptom Severity (NPI)

    The Neuropsychiatric Inventory (NPI) is a behavioral scale administered to the caregiver assessing 12 dimensions: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor activity, nighttime behaviors, and appetite/eating. Each dimension has multiple screening questions relating to symptoms. If the answer to the screening questions is "Yes", the dimensional-score is the product of frequency (1=occasionally to 4=very frequently) and severity (1=Mild to 3=Severe) of symptoms. Dimensional-scores are summed (from 0 to 144). Higher scores indicate greater behavioral disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.

    Time frame: Baseline, post tDCS (week 3)

  3. Change in Behavioral Symptom Severity (FBI)

    The Frontal Behavioral Inventory (FBI) is a 24-item inventory designed to assess behavior and personality changes via caregiver. Item-level scores range from 0=none, 1=mild/occasional, 2=moderate, 3=severe/most of the time. Item-scores are summed (from 0 to 72). Higher scores indicate greater behavioral/personality disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.

    Time frame: Baseline, post tDCS (week 3)

  4. Change in Functional Connectivity

    Default mode network (DMN) and salience network (SN) mean functional connectivity is assessed on resting state functional MRI. Functional connectivity is standardized to Z scores and thresholded at Z\>2. Higher values denote greater functional connectivity. A positive change at post tDCS compared to baseline represents an increase in resting-state functional connectivity.

    Time frame: Baseline, post tDCS (week 3)

  5. Change in Cerebral Blood Flow

    Default mode network (DMN) and salience network (SN) mean cerebral blood flow is assessed on arterial spin labeling. Cerebral blood flow is computed by averaging values across the DMN and SN regions of interest. Cerebral blood flow is a measure of brain perfusion, higher values denoting higher perfusion. A positive change at post tDCS compared to baseline represents an increase in perfusion.

    Time frame: Baseline, post tDCS (week 3)

Secondary outcomes

  1. Change in Cognition: Memory

    The composite memory score consists of the averaged Z-standardized scores of 5 memory tests: immediate and delayed auditory verbal learning test recall, Rey-Osterrieth complex figure recall, story recall, digit span backward and forward tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better memory performance. Positive changes at post tDCS compared to baseline represent an improvement in memory.

    Time frame: Baseline, post tDCS (week 3)

  2. Change in Cognition: Language

    The composite language score consists of the averaged Z-standardized scores of 2 language tests: verbal fluency and token tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better language performance. Positive changes at post tDCS compared to baseline represent an improvement in language.

    Time frame: Baseline, post tDCS (week 3)

  3. Change in Cognition: Executive Function

    The composite executive function score consists of the averaged Z-standardized scores of 2 executive functions tests: trail making test part A and part B tests. Each test score is normalized to an independent dataset of healthy controls and inverted. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better executive function performance. Positive changes at post tDCS compared to baseline represent an improvement in executive functions.

    Time frame: Baseline, post tDCS (week 3)

  4. Change in Cognition: Visuospatial Function

    The visuospatial function score consists of the Z-standardized scores for the Rey-Osterrieth complex figure copy test. Scores are normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better visuospatial performance. Positive changes at post tDCS compared to baseline represent an improvement in visuospatial functions.

    Time frame: Baseline, post tDCS (week 3)

  5. Change in Cognition: Emotion Recognition

    The composite emotion recognition score consists of the averaged Z-standardized scores for 2 emotion recognition tests: reading the Mind in the Eyes and 60 Ekman faces tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better emotion recognition performance. Positive changes at post tDCS compared to baseline represent an improvement in emotion recognition.

    Time frame: Baseline, post tDCS (week 3)

  6. Change in Structural Connectivity: FA

    Fractional anisotropy (FA) is assessed on diffusion weighted imaging. FA values are averaged in default mode network (DMN) and salience network (SN) regions of interest. FA values denote the directionality of water diffusivity, ranging from 0 (isotropic diffusion) to 1 (anisotropic diffusion). Higher values denote higher directionality and connectivity. Positive changes at post tDCS compared to baseline represent an improvement in the measure.

    Time frame: Baseline, post tDCS (week 3)

  7. Change in Structural Connectivity: MD, AxD, RaD

    Mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RaD) are assessed on diffusion weighted imaging. MD, AxD, RaD values are averaged in default mode network (DMN) and salience network (SN) regions of interest. MD, AxD, and RaD measure water diffusion and are expressed in mm\^2/s (starting from 0 with no maximum value; scaled at x10\^-3). Higher values denote higher diffusion and lower connectivity. Negative changes at post tDCS compared to baseline represent an improvement in the measure.

    Time frame: Baseline, post tDCS (week 3)

07

Results

Posted Apr 29, 2021

Participant flow

Intervention
Participant flow — Intervention
MilestoneAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Started11111211
Completed10101010
Not completed1121
Withdrew: Adverse event0101
Withdrew: Safety (psoriasis, cortical vascular lesions on mri)1020
Follow-up
Participant flow — Follow-up
MilestoneAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Started10101010
Completed1010108
Not completed0002
Withdrew: Withdrawal by subject0001
Withdrew: Adverse event0001

Outcome measures

PrimaryChange in Clinical Disease Severity (CDR)

CDR - Clinical Dementia Rating score The clinical dementia rating (CDR) is a clinical global rating scale administered to both the participant and the caregiver, assessing 6 domains of participant function: memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care. Each domain is based on a 5-point scale ranging from no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 to severe impairment=3. The global CDR score is computed via a memory-weighted averaging algorithm of the six domain scores and ranges from 0 to 5. The CDR-sum of boxes (CDR-SB) is the sum of the individual domain scores and ranges from 0 to 18. Higher scores indicate more clinical impairment. Negative changes at post tDCS compared to baseline represent an improvement on the scale.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · score on a scale
Change in Clinical Disease Severity (CDR)
score on a scaleAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
CDR global-0.1 ± 0.20.0 ± 0.00.0 ± 0.00.0 ± 0.0
CDR sum of boxes0.1 ± 0.40.0 ± 0.2-0.1 ± 0.30.0 ± 0.0
PrimaryChange in Behavioral Symptom Severity (NPI)

The Neuropsychiatric Inventory (NPI) is a behavioral scale administered to the caregiver assessing 12 dimensions: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor activity, nighttime behaviors, and appetite/eating. Each dimension has multiple screening questions relating to symptoms. If the answer to the screening questions is "Yes", the dimensional-score is the product of frequency (1=occasionally to 4=very frequently) and severity (1=Mild to 3=Severe) of symptoms. Dimensional-scores are summed (from 0 to 144). Higher scores indicate greater behavioral disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · score on a scale
Change in Behavioral Symptom Severity (NPI)
score on a scaleAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Change in Behavioral Symptom Severity (NPI)-1 ± 3-3 ± 6-1 ± 4-6 ± 11
PrimaryChange in Behavioral Symptom Severity (FBI)

The Frontal Behavioral Inventory (FBI) is a 24-item inventory designed to assess behavior and personality changes via caregiver. Item-level scores range from 0=none, 1=mild/occasional, 2=moderate, 3=severe/most of the time. Item-scores are summed (from 0 to 72). Higher scores indicate greater behavioral/personality disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · score on a scale
Change in Behavioral Symptom Severity (FBI)
score on a scalebvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Change in Behavioral Symptom Severity (FBI)-2 ± 4-4 ± 8
PrimaryChange in Functional Connectivity

Default mode network (DMN) and salience network (SN) mean functional connectivity is assessed on resting state functional MRI. Functional connectivity is standardized to Z scores and thresholded at Z\>2. Higher values denote greater functional connectivity. A positive change at post tDCS compared to baseline represents an increase in resting-state functional connectivity.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · Z-score
Change in Functional Connectivity
Z-scoreAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
DMN0.08 ± 0.13-0.09 ± 0.11-0.02 ± 0.23-0.04 ± 0.15
SN-0.06 ± 0.150.05 ± 0.20.08 ± 0.180.02 ± 0.12
PrimaryChange in Cerebral Blood Flow

Default mode network (DMN) and salience network (SN) mean cerebral blood flow is assessed on arterial spin labeling. Cerebral blood flow is computed by averaging values across the DMN and SN regions of interest. Cerebral blood flow is a measure of brain perfusion, higher values denoting higher perfusion. A positive change at post tDCS compared to baseline represents an increase in perfusion.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · ml/100g/min
Change in Cerebral Blood Flow
ml/100g/minAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
DMN4.87 ± 8.92-0.06 ± 9.460.56 ± 7.723.08 ± 3.45
SN4.37 ± 7.00-1.92 ± 12.32.34 ± 4.841.41 ± 4.09
SecondaryChange in Cognition: Memory

The composite memory score consists of the averaged Z-standardized scores of 5 memory tests: immediate and delayed auditory verbal learning test recall, Rey-Osterrieth complex figure recall, story recall, digit span backward and forward tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better memory performance. Positive changes at post tDCS compared to baseline represent an improvement in memory.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · z score
Change in Cognition: Memory
z scoreAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Change in Cognition: Memory0.3 ± 0.20.3 ± 0.30.1 ± 0.30.2 ± 0.3
SecondaryChange in Cognition: Language

The composite language score consists of the averaged Z-standardized scores of 2 language tests: verbal fluency and token tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better language performance. Positive changes at post tDCS compared to baseline represent an improvement in language.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · z score
Change in Cognition: Language
z scoreAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Change in Cognition: Language0.7 ± 0.60.4 ± 0.60.7 ± 0.90.4 ± 0.6
SecondaryChange in Cognition: Executive Function

The composite executive function score consists of the averaged Z-standardized scores of 2 executive functions tests: trail making test part A and part B tests. Each test score is normalized to an independent dataset of healthy controls and inverted. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better executive function performance. Positive changes at post tDCS compared to baseline represent an improvement in executive functions.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · z score
Change in Cognition: Executive Function
z scoreAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Change in Cognition: Executive Function0.3 ± 2.9-0.3 ± 2.40.7 ± 2.3-0.7 ± 1.6
SecondaryChange in Cognition: Visuospatial Function

The visuospatial function score consists of the Z-standardized scores for the Rey-Osterrieth complex figure copy test. Scores are normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better visuospatial performance. Positive changes at post tDCS compared to baseline represent an improvement in visuospatial functions.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · z score
Change in Cognition: Visuospatial Function
z scoreAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Change in Cognition: Visuospatial Function1.2 ± 1.10.0 ± 1.60.1 ± 0.80.4 ± 0.9
SecondaryChange in Cognition: Emotion Recognition

The composite emotion recognition score consists of the averaged Z-standardized scores for 2 emotion recognition tests: reading the Mind in the Eyes and 60 Ekman faces tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better emotion recognition performance. Positive changes at post tDCS compared to baseline represent an improvement in emotion recognition.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · z score
Change in Cognition: Emotion Recognition
z scoreAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Change in Cognition: Emotion Recognition0.1 ± 0.50.1 ± 0.60.3 ± 1.20.1 ± 0.9
SecondaryChange in Structural Connectivity: FA

Fractional anisotropy (FA) is assessed on diffusion weighted imaging. FA values are averaged in default mode network (DMN) and salience network (SN) regions of interest. FA values denote the directionality of water diffusivity, ranging from 0 (isotropic diffusion) to 1 (anisotropic diffusion). Higher values denote higher directionality and connectivity. Positive changes at post tDCS compared to baseline represent an improvement in the measure.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · score on a scale
Change in Structural Connectivity: FA
score on a scaleAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
DMN FA0.000 ± 0.007-0.003 ± 0.006-0.002 ± 0.0080.000 ± 0.008
SN FA0.003 ± 0.009-0.002 ± 0.011-0.002 ± 0.0090.001 ± 0.011
SecondaryChange in Structural Connectivity: MD, AxD, RaD

Mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RaD) are assessed on diffusion weighted imaging. MD, AxD, RaD values are averaged in default mode network (DMN) and salience network (SN) regions of interest. MD, AxD, and RaD measure water diffusion and are expressed in mm\^2/s (starting from 0 with no maximum value; scaled at x10\^-3). Higher values denote higher diffusion and lower connectivity. Negative changes at post tDCS compared to baseline represent an improvement in the measure.

Time frame:
Baseline, post tDCS (week 3)
Reported as:
Mean · x10^-3 mm^2/s
Change in Structural Connectivity: MD, AxD, RaD
x10^-3 mm^2/sAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
DMN MD-0.003 ± 0.017-0.001 ± 0.0190.007 ± 0.0080.007 ± 0.008
SN MD-0.004 ± 0.016-0.002 ± 0.0170.010 ± 0.0090.007 ± 0.008
DMN AxD-0.004 ± 0.017-0.006 ± 0.0240.009 ± 0.0140.008 ± 0.011
SN AxD-0.004 ± 0.017-0.008 ± 0.0290.014 ± 0.0180.010 ± 0.012
DMN RaD-0.002 ± 0.0170.001 ± 0.0170.007 ± 0.0090.006 ± 0.009
SN RaD-0.005 ± 0.0170.000 ± 0.0150.008 ± 0.0090.005 ± 0.011

Adverse events

Collected over Adverse events were monitored from the time of enrollment to follow-up assessment (approx 6 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AD: Anodal tDCS of the DMN0/11 (0%)0/11 (0%)5/11 (45.5%)
AD: Cathodal tDCS of the SN0/11 (0%)0/11 (0%)6/11 (54.5%)
bvFTD: Anodal tDCS of the SN0/12 (0%)0/12 (0%)5/12 (41.7%)
bvFTD: Cathodal tDCS of the DMN0/11 (0%)1/11 (9.1%)5/11 (45.5%)
Most frequent serious events
Most frequent serious events
EventAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Intestinal infarctGastrointestinal disorders0/110/110/121/11
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMN
Pinching (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders5/115/113/121/11
Itching (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders0/113/111/121/11
FatigueGeneral disorders2/111/110/120/11
Burning (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders2/111/110/122/11
Chest painGeneral disorders0/111/110/120/11
DizzinessNervous system disorders0/111/110/121/11
HeadacheNervous system disorders0/110/110/121/11
FallInjury, poisoning and procedural complications0/110/110/121/11
Pain (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders1/110/110/120/11
Warmth/Heat (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders0/111/110/120/11

Baseline characteristics

Modified intention-to-treat sample (participants completing intervention)

Age, Continuous
Age, Continuous(years)AD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMNTotal
Mean72 ± 673 ± 671 ± 1069 ± 1171 ± 8
Sex/Gender, Customized
Sex/Gender, Customized(Participants)AD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMNTotal
Female643518
Male467522
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMNTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1010101040
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)AD: Anodal tDCS of the DMNAD: Cathodal tDCS of the SNbvFTD: Anodal tDCS of the SNbvFTD: Cathodal tDCS of the DMNTotal
Italy1010101040
08

Study locations

1 site
  • IRCCS Centro San Giovanni di Dio Fatebenefratelli
    Brescia, 25125, Italy
09

References and documents

Publications

  • Pievani M, Pini L, Cappa SF, Frisoni GB. Brain networks stimulation in dementia: insights from functional imaging. Curr Opin Neurol. 2016 Dec;29(6):756-762. doi: 10.1097/WCO.0000000000000387. PubMed 27661207 ↗
  • Pini L, Pizzini FB, Boscolo-Galazzo I, Ferrari C, Galluzzi S, Cotelli M, Gobbi E, Cattaneo A, Cotelli MS, Geroldi C, Zanetti O, Corbetta M, van den Heuvel M, Frisoni GB, Manenti R, Pievani M. Brain network modulation in Alzheimer's and frontotemporal dementia with transcranial electrical stimulation. Neurobiol Aging. 2022 Mar;111:24-34. doi: 10.1016/j.neurobiolaging.2021.11.005. Epub 2021 Nov 20. PubMed 34942516 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Nov 2018, 40 months.

Results were first posted in Apr 2021, 2 years 5 months after primary completion.

Of 886 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 40 months is above that.

Counting every sponsor, half of 963 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Feb 5, 2018
StartActual
Jun 8, 2015
Primary completionActual
Nov 3, 2018
CompletionActual
Nov 3, 2018
Results first posted
Apr 29, 2021
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03422250
Lead sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Responsible party
Michela Pievani (Principal Investigator, IRCCS Centro San Giovanni di Dio Fatebenefratelli) — Principal investigator
First posted
Feb 5, 2018
Start date
Jun 8, 2015
Primary completion
Nov 3, 2018
Completion
Nov 3, 2018
Results posted
Apr 29, 2021
Last update
May 19, 2021

Study contacts

Michela Pievani, PhD
principal investigator · IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion